Suzhou Leadsynbio Technology Co., Ltd, a specialist in synthetic biology, has reported raised hundreds of millions of dollars of renminbi in a Series D finance round. The round was backed by existing investors Lily Asia Ventures and Sherpa Healthcare Partners. The proceedings from this funding will be allocated to bolder research and development (R&D), enhancing business layout, strengthen team building, and increase market and product competitiveness.
Global Presence and R&D Capabilities
Founded in 2015, Leadsynbio has established a robust global presence with two R&D centers located in Suzhou and the US, and two plants in Hunan and Anhui provinces in China. The company boasts an R&D workforce exceeding 130 professionals, demonstrating its commitment to innovation and growth in the field of synthetic biology.
Investor Confidence and Future Outlook
The support from Lilly Asia Ventures and Sherpa Healthcare Partners reflects investor confidence in Leadsynbio’s potential and its track record of success. With the new funds, the company is poised to accelerate its R&D efforts, expand its business operations, and strengthen its market position, positioning itself as a leader in the synthetic biology sector.-Fineline Info & Tech
